Kinnate Biopharma Valuation
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Kinnate Biopharma secures a last-minute Real Value of $2.71 per share. The latest price of the firm is $2.96. Our model forecasts the value of Kinnate Biopharma from analyzing the firm fundamentals such as Return On Equity of -0.56, current valuation of (25.71 M), and Shares Owned By Insiders of 0.15 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Kinnate Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Kinnate Biopharma is based on 3 months time horizon. Increasing Kinnate Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Kinnate stock is determined by what a typical buyer is willing to pay for full or partial control of Kinnate Biopharma. Since Kinnate Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kinnate Stock. However, Kinnate Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.96 | Real 2.71 | Hype 2.96 | Naive 2.76 |
The real value of Kinnate Stock, also known as its intrinsic value, is the underlying worth of Kinnate Biopharma Company, which is reflected in its stock price. It is based on Kinnate Biopharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kinnate Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kinnate Biopharma helps investors to forecast how Kinnate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kinnate Biopharma more accurately as focusing exclusively on Kinnate Biopharma's fundamentals will not take into account other important factors: Kinnate Biopharma Total Value Analysis
Kinnate Biopharma is now anticipated to have valuation of (25.71 M) with market capitalization of 124.99 M, debt of 3.17 M, and cash on hands of 262.42 M. The negative valuation of Kinnate Biopharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kinnate Biopharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(25.71 M) | 124.99 M | 3.17 M | 262.42 M |
Kinnate Biopharma Asset Utilization
One of the ways to look at asset utilization of Kinnate is to check how much profit was generated for every dollar of assets it reports. Kinnate Biopharma secures a negative usage of assets of -0.34 %, losing $0.003363 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kinnate Biopharma shows how discouraging it operates for each dollar spent on its assets.Kinnate Biopharma Ownership Allocation
Kinnate Biopharma maintains a total of 47.17 Million outstanding shares. The majority of Kinnate Biopharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kinnate Biopharma to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kinnate Biopharma. Please pay attention to any change in the institutional holdings of Kinnate Biopharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kinnate Biopharma Profitability Analysis
Net Loss for the year was (112.65 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kinnate Biopharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kinnate Biopharma and how it compares across the competition.
About Kinnate Biopharma Valuation
The delisted stock valuation mechanism determines Kinnate Biopharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Kinnate Biopharma. We calculate exposure to Kinnate Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kinnate Biopharma's related companies.Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC. Kinnate Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
Kinnate Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Kinnate Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 46.6 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |